|
|
 |
|
Viewing report
|
|
|
|
Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD
GBI Research, Nov 2011, Pages: 76
GBI Research’s report, “Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD”, provides an in-depth analysis of patient recruitment scenario for major indications under respiratory diseases. The report analyzes the number of clinical trials conducted for major indications. The report provides information about the total number of clinical trials conducted by phase, geography, major sponsors and the number of clinical trials conducted per year. Analysis of the total number of patients recruited for major indications is also carried out. The report analyzes the total number of patients recruited by phase of clinical trial, geography and major sponsors. Analysis of the average number of patients recruited per trial per year for various indications is also completed.
Clinical trials are conducted to find novel therapies for respiratory diseases. The cost and time for conducting clinical trials for respiratory diseases is higher than other diseases. This is due to costly and time consuming testing methods. Patients are required to be tested for a longer duration leading to an increase in the total time required for drug effectiveness than seen in other diseases. Changing environmental conditions along with increases in tobacco smoking, air pollution and urbanization has lead to an increase in the prevalence of respiratory diseases. Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF) and Pulmonary Arterial Hypertension (PAH) are few of the major respiratory diseases for which an increased number of clinical trials are conducted in order to determine the most effective treatment.
In accordance to World Health Organization (WHO), the most common chronic disease among children is asthma. Asthma affects nearly 235 million people in the world. COPD was the cause of 5% of the total deaths in 2005. Tobacco smoking is the leading cause of COPD and in 2030. COPD will be the third leading cause of death. In light if this it becomes more important to find remedies for chronic respiratory diseases. CF is one of the most prevalent life-shortening diseases. It is a genetic disease which affects multiple organs.
It is important to recruit the right type and number of patients to check the efficacy and efficiency of drugs. Efficient patient recruitment leads to a decrease in the time and cost associated with patient recruitment. At present, the rate of new drug approvals is declining with every passing year. Pharmaceutical companies are under intense pressure to reduce the time required for drug development. There are many barriers to participation for the patients as well as the investigators who enroll patients into the trials. Advances in the diagnosis and treatment of respiratory diseases are leading to a greater interest of pharmaceutical companies in sponsoring research into respiratory diseases.
Scope
- Insight on Clinical Trials conducted for major indications of respiratory diseases such as asthma, COPD, CF, PAH or Pulmonary Hypertension (PH) for the period 2000–2010.
- The status of patient recruitment by geographical region, sponsor company, year and stage of development.
- Analysis on the average number of patients recruited per trial for major indications per year.
- Analysis on the average number of patients recruited per trial for major indications by stage of development.
- The prevalence population in India, China and Brazil for all major indications from 2010-2017.
Reasons to buy
- Identify and understand the status of clinical trials conducted for major respiratory indications from 2000-2010.
- Build understanding of patient recruitment status by geography, sponsor company, year and stage of development.
- Identify the prevalence population for the major indications till 2017.
- Identify the average number of patients recruited by stage of development and across years for all major indications.
- Identify the indication in which the maximum number of trials is conducted and and to which the maximum number of patients are recruited.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
